NCT06303583 (CRIS) is a Phase 1, PHASE2 clinical trial of paclitaxel in Esophageal Squamous Cell Carcinoma, sponsored by Qiu Guoqin.

Who is sponsoring NCT06303583?

NCT06303583 is sponsored by Qiu Guoqin.

What drugs are being tested in NCT06303583?

Interventions in NCT06303583: paclitaxel, carboplatin, tislelizumab, radiotherapy.

What condition does NCT06303583 study?

NCT06303583 studies Esophageal Squamous Cell Carcinoma.

Is NCT06303583 still recruiting?

NCT06303583 is currently enrolling by invitation. Last updated 12 March 2024.

Last reviewed 2024-03-12 · How we verify

NCT06303583: CRIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

ENROLLING BY INVITATION Phase 1, PHASE2 Last updated 12 March 2024

What this trial tests

Phase 1, PHASE2 trial testing paclitaxel in Esophageal Squamous Cell Carcinoma in 30 participants. Enrolling by invitation.

Timeline

1 June 2022

Primary endpoint
31 August 2024

31 December 2026

Quick facts

Lead sponsor	Qiu Guoqin
Phase	Phase 1, PHASE2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2022
Primary completion	31 August 2024
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

paclitaxel — full drug profile →
carboplatin (Carboplatin) — full drug profile →
tislelizumab (TISLELIZUMAB) — full drug profile →
radiotherapy — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Qiu Guoqin

Who can join

Adults 18 to 75, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radiotherapy combined with immunotherapy for esophageal cancer: current status and challenge.
Wang Y, Gu J, Sun X. · · 2026 · PMID 42069985 · DOI 10.1007/s00432-026-06480-2

Verify or expand the search:

Other trials of paclitaxel

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06584032 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · Phase 3 · recruiting
NCT05904379 — AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · active not recruiting
NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06303583 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qiu Guoqin
Last refreshed: 12 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06303583.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing